Eli Lilly is channeling billions from its weight-loss franchise into a sweeping acquisition strategy aimed at blood cancer, neuroscience and immunology. The latest move came Monday, when the company agreed to acquire Calytrix Bio for up to $1.5 billion in cash for a rare blood cancer treatment that has not yet been tested in humans, according to the Observer.
The Financial Engine Behind the Buying Spree
The firepower comes from Mounjaro and Zepbound, the twin GLP-1 blockbusters that generated roughly $16 billion in the third quarter alone. That figure represents nearly two-thirds of Lilly’s total revenue, which jumped 39 percent to $24.4 billion in the three months through September. The company has raised its 2026 revenue forecast to between $91 billion and $92 billion.
That cash flow has made Lilly the busiest buyer of biotech companies this year, with 15 acquisitions valued at more than $30 billion announced so far, according to biotech trade publication BioPharma Dive. By comparison, GSK, Gilead Sciences and Novartis have each completed three deals in the same period.
Betting Before Human Trials
The Calytrix deal illustrates how early Lilly is willing to go. Founded in 2025 by J.P. Morgan Life Sciences Private Capital, the Wellesley Hills, Massachusetts biotech is developing an antibody that targets mutated calreticulin, or mCALR, a genetic driver of essential thrombocythemia and myelofibrosis, two rare blood cancers known as myeloproliferative neoplasms. Current treatments largely manage symptoms; Calytrix’s experimental therapy is designed to target the abnormal cells driving the disease while sparing healthy blood-forming cells. But the program remains preclinical, with no human testing yet underway.

Lilly will pay an undisclosed upfront amount, with the remaining value tied to clinical and regulatory milestones. If successful, the asset would complement Jaypirca, Lilly’s approved blood cancer medicine, and give the company a potential therapy that goes beyond symptom management to address an underlying disease driver.
A Strategy Shaped by Ricks’ Own Scientific Roots
David Ricks has led Eli Lilly as CEO since 2017 and added the chair role later that year. Before reaching the top job, he spent three decades at the company in roles spanning business development, marketing, country management in Canada and China, and leadership of the Bio-Medicines unit that oversaw neuroscience, pain and immunology drug development. That background helps explain the therapeutic focus of the current buying spree: blood cancer, neuroscience and immunology are areas Ricks knows from the lab bench to the commercial launch.
Building the Factory Floor at the Same Time
While Ricks shops for early-stage science abroad, he is also pouring capital into domestic manufacturing. Lilly broke ground November 12 on a $3.5 billion campus in Pennsylvania’s Lehigh Valley, one of ten new U.S. sites announced since 2020 and part of a $50 billion push to expand production at home. The facility will eventually produce next-generation GLP-1 injectables, including the experimental triple agonist retatrutide, and is expected to create 850 permanent high-wage jobs alongside 2,000 construction roles. “This site will be one of the most technically advanced, not just in Lilly, but in the industry,” Ricks said at the groundbreaking. “It will be a source of good jobs for this region, and most importantly a source for medicines made in Pennsylvania for patients here and around the world.”
The dual track — aggressive external innovation paired with massive internal scale — reflects a CEO who spent his career inside the company’s own labs and factories before taking the helm. For families waiting on new options in blood cancer or neurodegenerative disease, the question now is how quickly those preclinical bets can translate into human data. Lilly’s next quarterly earnings report will offer the latest measure of whether the GLP-1 engine can keep funding the search.
Sources
- Eli Lilly CEO David Ricks Is Using the Weight-Loss Boom to Buy His Next Bet
- David A. Ricks
- Lehigh Valley Cheers a New Era of Manufacturing as Lilly Breaks Ground
- Eli Lilly to create 2,000 construction jobs in Pennsylvania with $3.5bn new facility
- Rick Shiels hits back after catching strays from LIV Golf’s Chief Restructuring Officer
- 'Never Heard of Him': LIV Golf Executive Drops Bizarre Courtroom Response to $1.4M Creditor Rick Shiels
Photo: Trnava University / Unsplash (Unsplash License)





